| Related Articles |
Pirfenidone improves the survival of patients with idiopathic pulmonary fibrosis hospitalized for acute exacerbation.
Curr Med Res Opin. 2019 Jan 05;:1
Authors: Vianello A, Molena B, Turato C, Braccioni F, Arcaro G, Paladini L, Andretta M, Saetta M
Abstract
OBJECTIVE: To examine the effect of pirfenidone on the survival of patients hospitalized due to acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF).
METHODS: The outcomes of 11 consecutive AE-IPF patients who were receiving pirfenidone treatment when they were admitted to a respiratory intensive care unit (RICU) for acute respiratory failure (ARF) (treatment group) were retrospectively compared with those of 9 patients who were not on pirfenidone treatment at admission (control group). The study's primary outcome measure was survival following RICU admission; the patients' mortality rate and the length of time spent in the RICU were also assessed.
RESULTS: The treatment group had a significantly longer survival with respect to the control group [median survival time:137.0 (95%CI, 39.0 to 373.0) vs 16.0 (95%CI, 14.0 to 22.0) days; p = 0.0009]; the hazard ratio for death was 0.2896 (95% CI, 0.09541 to 0.8791). The treatment group also tended to have a lower RICU mortality rate (3/11 vs 7/9; p= 0.0698).
CONCLUSIONS: Pirfenidone significantly improved survival in the IPF patients hospitalized for severe acute exacerbation with respect to their counterparts.
PMID: 30612467 [PubMed - as supplied by publisher]